US OptionsDetailed Quotes
DRRX250417P2000
- 0.66
- 0.000.00%
15min DelayClose Apr 9 15:59 ET
0.00High0.00Low
0.66Open0.66Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-87.94%PremiumApr 17, 2025Expiry Date1.29Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Durect Stock Discussion
Sign in to post a comment
$Durect (DRRX.US)$
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Tuesday, 28th January at 10:09 am
The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial
CUPERTINO, Calif., Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full a...
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Tuesday, 28th January at 10:09 am
The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial
CUPERTINO, Calif., Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full a...
1
$Durect (DRRX.US)$
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT (DRRX) has sold its ALZET® osmotic pumps product line to Lafayette Instrument Co. for $17.5 million. The transaction includes certain assets and liabilities associated with the ALZET line.
DURECT used the proceeds to pay off its remaining obligations under the Oxford Finance term loan.
The company states this sale strengthens its cash position and extends runway t...
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT (DRRX) has sold its ALZET® osmotic pumps product line to Lafayette Instrument Co. for $17.5 million. The transaction includes certain assets and liabilities associated with the ALZET line.
DURECT used the proceeds to pay off its remaining obligations under the Oxford Finance term loan.
The company states this sale strengthens its cash position and extends runway t...
4
$Durect (DRRX.US)$
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
- Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
- Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
20
3
3
$Durect (DRRX.US)$ Reuters· 1 min ago
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation and Charles River Laboratories: A Strategic Alliance Set to Revolutionize the Biopharmaceutical Industry.
In a significant move within the biopharmaceutical industry, DURECT Corporation (DRRX) has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. This alliance, announced on March 4, 2024, is set to jointly market and commercialize the ALZET Osmotic Pumps ...
In a significant move within the biopharmaceutical industry, DURECT Corporation (DRRX) has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. This alliance, announced on March 4, 2024, is set to jointly market and commercialize the ALZET Osmotic Pumps ...
$Durect (DRRX.US)$ Durect Corporation Has Entered Into A Co-marketing And Collaboration Agreement With Charles River Laboratories For The Alzet Osmotic Pumps Portfolio And Associated Product Line In The US And Canada
2
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
151323992 : This one looks promising